| In millions, except per share items | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 |
| | 10-K | 10-K | 10-K | S-1/A |
| Revenues: |
| Revenue from Discontinued Operations | 59.4 | 74.2 | | |
| Government Health Benefit Programs | | | 0.2 | |
| Patient/Laboratory Distribution Partners | | | 4.7 | |
| Commercial Third-party Payors | | | 139.1 | |
| Total revenues | 1.2 | 0.2 | 144.0 | 128.0 |
| Revenue growth [+] | 669.8% | -99.9% | 12.5% | |
| Revenue from Discontinued Operations | -19.9% | | | |
| Cost of goods sold | 0.0 | 0.0 | 100.5 | 92.1 |
| Gross profit | 1.2 | 0.2 | 43.5 | 35.9 |
| Gross margin | 100.0% | 100.0% | 30.2% | 28.1% |
| Selling, general and administrative [+] | 4.8 | 5.9 | 120.2 | 101.4 |
| Sales and marketing | 4.8 | 5.9 | 58.9 | 50.2 |
| General and administrative | | | 61.3 | 51.2 |
| Research and development | | | 63.4 | 48.7 |
| Equity in earnings | | | | -2.3 |
| Other operating expenses | 115.0 | 161.9 | | |
| EBITDA [+] | -117.1 | -166.3 | -135.4 | -110.5 |
| EBITDA growth | -29.6% | 22.8% | 22.6% | |
| EBITDA margin | -9387.0% | -102632.1% | -94.1% | -86.3% |
| Depreciation | 0.9 | 0.5 | 3.8 | 6.1 |
| EBITA | -118.0 | -166.8 | -139.2 | -116.6 |
| EBITA margin | -9462.1% | -102964.2% | -96.7% | -91.1% |
| Amortization of intangibles | 0.5 | 0.9 | 0.9 | |
| EBIT [+] | -118.5 | -167.7 | -140.1 | -116.6 |
| EBIT growth | -29.3% | 19.7% | 20.2% | |
| EBIT margin | -9502.2% | -103519.8% | -97.3% | -91.1% |
| Interest expense | | | 9.2 | 9.1 |
| Interest expense | 12.6 | 9.9 | 9.2 | 9.1 |
| Other income (expense), net | -47.5 | 35.0 | 0.6 | 1.8 |
| Pre-tax income | -178.6 | -142.6 | -148.7 | -123.9 |
| Income taxes | -0.1 | -37.5 | -0.7 | 5.3 |
| Tax rate | 0.1% | 26.3% | 0.5% | |
| Net income | -247.4 | -192.5 | -228.8 | -0.1 |
| Net margin | -19840.6% | -118844.4% | -158.9% | -0.1% |
| |
| Basic EPS [+] | ($1.86) | ($3.82) | ($46.87) | ($27.72) |
| Growth | -51.4% | -91.8% | 69.1% | |
| Diluted EPS [+] | ($1.86) | ($3.82) | ($46.87) | ($27.72) |
| Growth | -51.4% | -91.8% | 69.1% | |
| |
| Dividends per share [+] | | | $0.92 | |
| Growth | | -100.0% | | |
| |
| Shares outstanding (basic) [+] | 96.2 | 27.5 | 4.9 | 0.0 |
| Growth | 249.5% | 463.5% | 104738.1% | |
| Shares outstanding (diluted) [+] | 96.2 | 27.5 | 4.9 | 0.0 |
| Growth | 249.5% | 463.5% | 104738.1% | |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |